Skip to main content

Featured

5 Things to Know Today: BoC Hike Odds, Fixed Rates, Tariff Swap, $100 Oil & Budget Countdown (Oct. 25)

  Canadian Money Brief • Sunday, October 25, 2026 A big week for your wallet starts Wednesday. Here are the five things Canadians should know before it begins. 1 The Bank of Canada decides Wednesday, and markets lean toward a hike The Bank of Canada announces its rate decision at 9:45 a.m. ET on Wednesday, Oct. 28, alongside a new Monetary Policy Report. Prediction markets price roughly a 79% chance of a quarter-point hike to 2.50%, up sharply after Governor Tiff Macklem’s hawkish comments at the IMF meetings, though analysts remain split and some expect a “hawkish hold.” The U.S. Fed also decides that day. What it means for you: Variable-rate mortgage and HELOC holders feel it first. A 0.25-point hike works out to roughly $70 more per month on a $500,000 variable mortgage (25-year amortization), and prime would move from 4.45% to 4.70%. A hold means little change until the next decision on Dec. 9. 2 Fixed mortgage rates have already moved without the Bank Fixed rates follow bond ...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment